C07D 237/34
With nitrogen atoms directly attached to carbon atoms of the nitrogen-containing ring
Official title: with nitrogen atoms directly attached to carbon atoms of the nitrogen-containing ring, e.g. hydrazine radicals
C07D237/34 (With nitrogen atoms directly attached to carbon atoms of the nitrogen-containing ring) appears on 101 US grants and 105 published applications in this corpus.
Search patents in C07D- Granted patents
- 101
- Published applications
- 105
- Assignees
- 84
- Inventors
- 429
- Latest grant
- 27 Jan 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1977 | 1 | 0 |
| 1978 | 1 | 0 |
| 1979 | 0 | 0 |
| 1980 | 0 | 0 |
| 1981 | 0 | 0 |
| 1982 | 0 | 0 |
| 1983 | 1 | 0 |
| 1984 | 1 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 4 | 0 |
| 1988 | 2 | 0 |
| 1989 | 1 | 0 |
| 1990 | 2 | 0 |
| 1991 | 0 | 0 |
| 1992 | 1 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 1 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 1 | 0 |
| 1999 | 0 | 0 |
| 2000 | 2 | 0 |
| 2001 | 8 | 1 |
| 2002 | 9 | 4 |
| 2003 | 2 | 7 |
| 2004 | 4 | 4 |
| 2005 | 2 | 3 |
| 2006 | 1 | 4 |
| 2007 | 3 | 5 |
| 2008 | 3 | 9 |
| 2009 | 1 | 3 |
| 2010 | 5 | 3 |
| 2011 | 3 | 4 |
| 2012 | 4 | 4 |
| 2013 | 5 | 4 |
| 2014 | 3 | 5 |
| 2015 | 8 | 3 |
| 2016 | 2 | 3 |
| 2017 | 2 | 1 |
| 2018 | 1 | 2 |
| 2019 | 2 | 1 |
| 2020 | 1 | 1 |
| 2021 | 1 | 3 |
| 2022 | 2 | 2 |
| 2023 | 1 | 4 |
| 2024 | 2 | 14 |
| 2025 | 7 | 7 |
| 2026 | 1 | 4 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Phthalazine derivatives as P2X3 inhibitors27 Jan 2026US 12,534,455 B2Chiesi Farmaceutici S.P. A.
- Compounds and their use23 Dec 2025US 12,503,445 B2AstraZeneca AB
- Pyridazine compounds for inhibiting NLRP314 Oct 2025US 12,441,728 B2Ventus Therapeutics U.S., Inc.
- Pyridazine compounds for inhibiting NLRP39 Sep 2025US 12,410,167 B2Ventus Therapeutics U.S., Inc.
- Compounds for inhibiting NLRP3 and uses thereof8 Jul 2025US 12,351,578 B2Ventus Therapeutics U.S., Inc.
- Pyridazine nlrp3 inhibitor compound, pharmaceutical composition, and preparation method therefor and use thereof30 Jul 2026US 2026/0216182 A1Changchun Genescience Pharmaceutical Co., Ltd.
- Nlrp3 inflammasome inhibitors16 Jul 2026US 2026/0200914 A1AstraZeneca AB
- Pyridazine compounds for inhibiting nlrp34 Jun 2026US 2026/0152500 A1Ventus Therapeutics U.S., Inc.
- Pyridazine compounds for inhibiting nlrp312 Feb 2026US 2026/0042757 A1Ventus Therapeutics U.S., Inc.
- Sos1 inhibitors28 Aug 2025US 2025/0270220 A1Mirati Therapeutics, Inc.
Most cited
By later US patents
- Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity78US 6,121,278 AGuilford Pharmaceuticals Inc. · 2000
- KRAS G12C inhibitors and methods of using the same60US 10,519,146 B2Amgen Inc. · 2019
- Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity50US 6,197,785 B1Guilford Pharmaceuticals Inc. · 2001
- Fused pyridazine compounds38US 5,849,741 AEisai Co., Ltd. · 1998
- Phthalazine derivatives as phosphodiesterase 4 inhibitors31US 6,498,160 B2Zambon Group S.p.A. · 2002